RU2020113494A - Имплантаты с замедленным высвобождением для снижения внутриглазного давления с увеличенной продолжительностью действия - Google Patents

Имплантаты с замедленным высвобождением для снижения внутриглазного давления с увеличенной продолжительностью действия Download PDF

Info

Publication number
RU2020113494A
RU2020113494A RU2020113494A RU2020113494A RU2020113494A RU 2020113494 A RU2020113494 A RU 2020113494A RU 2020113494 A RU2020113494 A RU 2020113494A RU 2020113494 A RU2020113494 A RU 2020113494A RU 2020113494 A RU2020113494 A RU 2020113494A
Authority
RU
Russia
Prior art keywords
implant
lactide
poly
patient
months
Prior art date
Application number
RU2020113494A
Other languages
English (en)
Russian (ru)
Other versions
RU2020113494A3 (https=
Inventor
Майкл Р. РОБИНСОН
Марина БЕЖАНЯН
Мишель И. ЧЭНЬ
Original Assignee
Аллерган, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Аллерган, Инк. filed Critical Аллерган, Инк.
Publication of RU2020113494A3 publication Critical patent/RU2020113494A3/ru
Publication of RU2020113494A publication Critical patent/RU2020113494A/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/0008—Introducing ophthalmic products into the ocular cavity or retaining products therein
    • A61F9/0017—Introducing ophthalmic products into the ocular cavity or retaining products therein implantable in, or in contact with, the eye, e.g. ocular inserts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/007—Methods or devices for eye surgery
    • A61F9/00781—Apparatus for modifying intraocular pressure, e.g. for glaucoma treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Surgery (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Prostheses (AREA)
RU2020113494A 2017-11-09 2018-11-09 Имплантаты с замедленным высвобождением для снижения внутриглазного давления с увеличенной продолжительностью действия RU2020113494A (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762583967P 2017-11-09 2017-11-09
US62/583,967 2017-11-09
US201862683337P 2018-06-11 2018-06-11
US62/683,337 2018-06-11
PCT/US2018/059910 WO2019094652A1 (en) 2017-11-09 2018-11-09 Sustained-release implants for lowering intraocular pressure with extended duration of effect

Publications (2)

Publication Number Publication Date
RU2020113494A3 RU2020113494A3 (https=) 2021-12-09
RU2020113494A true RU2020113494A (ru) 2021-12-09

Family

ID=64457124

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2020113494A RU2020113494A (ru) 2017-11-09 2018-11-09 Имплантаты с замедленным высвобождением для снижения внутриглазного давления с увеличенной продолжительностью действия

Country Status (16)

Country Link
US (2) US20190192341A1 (https=)
EP (1) EP3706717A1 (https=)
JP (2) JP2021502366A (https=)
KR (1) KR20200086289A (https=)
CN (1) CN111315361A (https=)
AU (2) AU2018366214B2 (https=)
BR (1) BR112020009224A2 (https=)
CA (1) CA3080908A1 (https=)
CL (1) CL2020001183A1 (https=)
CO (1) CO2020006924A2 (https=)
IL (1) IL273946A (https=)
MX (2) MX2020004730A (https=)
PH (1) PH12020550550A1 (https=)
RU (1) RU2020113494A (https=)
SG (1) SG11202004126XA (https=)
WO (1) WO2019094652A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3062775T (pt) * 2013-10-31 2018-03-06 Allergan Inc Implantes intraoculares contendo prostamida e métodos para a sua utilização
AU2020302924A1 (en) 2019-06-27 2022-02-17 Layerbio, Inc. Ocular device delivery methods and systems
PT3861985T (pt) 2020-02-06 2023-08-03 Ocular Therapeutix Inc Composições e métodos para tratar doenças oculares
PT3884929T (pt) 2020-03-25 2023-08-09 Ocular Therapeutix Inc Implante ocular contendo um inibidor da tirosina cinase
WO2022011321A1 (en) 2020-07-10 2022-01-13 Allergan, Inc. Posterior chamber delivery device for sustained release implant
TW202216159A (zh) * 2020-07-21 2022-05-01 美商歐樂根公司 具高負載前列腺素醯胺之眼內植入物
PE20260040A1 (es) 2023-04-11 2026-01-09 Ocular Therapeutix Inc Implante ocular que contiene un inhibidor de la tirosina cinasa

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5688819A (en) 1992-09-21 1997-11-18 Allergan Cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
US5834498A (en) 1992-09-21 1998-11-10 Allergan Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
US7993634B2 (en) * 2004-04-30 2011-08-09 Allergan, Inc. Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods
US7799336B2 (en) 2004-04-30 2010-09-21 Allergan, Inc. Hypotensive lipid-containing biodegradable intraocular implants and related methods
CN102821753A (zh) * 2010-01-22 2012-12-12 阿勒根公司 前房内持续释放治疗药植入物
US20120276186A1 (en) * 2011-04-29 2012-11-01 Ghebremeskel Alazar N Sustained release latanoprost implant
PT3062775T (pt) * 2013-10-31 2018-03-06 Allergan Inc Implantes intraoculares contendo prostamida e métodos para a sua utilização
US20160296627A1 (en) * 2013-12-06 2016-10-13 Envisia Therapeutics Inc. Intracameral implant for treatment of an ocular condition
WO2017015675A1 (en) * 2015-07-23 2017-01-26 Envisia Therapeutics, Inc. Glaucoma treatment via intracameral ocular implants

Also Published As

Publication number Publication date
MX2023011426A (es) 2023-10-17
CL2020001183A1 (es) 2020-11-06
MX2020004730A (es) 2020-08-13
KR20200086289A (ko) 2020-07-16
CA3080908A1 (en) 2019-05-16
JP2024032731A (ja) 2024-03-12
SG11202004126XA (en) 2020-06-29
PH12020550550A1 (en) 2021-03-22
EP3706717A1 (en) 2020-09-16
US20190192341A1 (en) 2019-06-27
AU2018366214B2 (en) 2024-11-14
US20240130890A1 (en) 2024-04-25
US20240225893A9 (en) 2024-07-11
RU2020113494A3 (https=) 2021-12-09
CO2020006924A2 (es) 2020-06-19
AU2024227541A1 (en) 2024-11-14
IL273946A (en) 2020-05-31
JP2021502366A (ja) 2021-01-28
CN111315361A (zh) 2020-06-19
WO2019094652A1 (en) 2019-05-16
BR112020009224A2 (pt) 2020-10-13
AU2018366214A1 (en) 2020-05-14

Similar Documents

Publication Publication Date Title
RU2020113494A (ru) Имплантаты с замедленным высвобождением для снижения внутриглазного давления с увеличенной продолжительностью действия
RU2532333C2 (ru) Внутриглазные системы доставки лекарственного средства с замедленным высвобождением и способы лечения глазных заболеваний
BRPI0708622A2 (pt) terapia ocular usando agentes que ativam a sirtuina
RU2016116378A (ru) Внутриглазные имплантаты, содержащие простамид, и способы их применения
CN116077665A (zh) 用于治疗眼科疾病和障碍的化合物
US20090209983A1 (en) Polyhydroxyalkanoate nerve regeneration devices
ES2819215T5 (en) Methods of treatment of ocular conditions with a sustained drug delivery implant
JP2021502366A5 (https=)
WO2014066658A1 (en) Ketorolac-containing sustained release drug delivery systems
US20240226053A9 (en) Compositions for ophthalmic care
US6945971B1 (en) Controlled ocular lens regeneration
US11298337B2 (en) Parthenolide and its derivative for use in the treatment of axonal damage
US10272035B2 (en) Ophthalmic drug delivery method
RU2613413C1 (ru) Дренаж для хирургического лечения глаукомы
US8802651B2 (en) Hyaluronic acid in the enhancement of lens regeneration
Liu et al. Prevention effect of medical self-crosslinking sodium hyaluronate gel on epidural scar adhesion after laminectomy
WO2007064543A1 (en) Hyaluronic acid and hyaluronidase in the enhancement of lens regeneration
RU2398557C1 (ru) Способ лечения вторичной факоморфической глаукомы
RU2409333C1 (ru) Способ факоэмульсификации травматической катаракты, осложненной иридодиализом
RU2496456C2 (ru) СПОСОБ ИНТРАСКЛЕРАЛЬНОЙ ФИКСАЦИИ ДРЕНАЖНОЙ ТРУБКИ КЛАПАНА AhmedTMGlaucoma Valve
RU2327440C1 (ru) Способ хирургического лечения глаукомы
RU2248779C1 (ru) Способ восстановления угла передней камеры при его органической блокаде
Rosa et al. Reposicionamento não cirúrgico de fragmento de implante de dexametasona (ozurdex®) em caso de migração para câmara anterior
BR102016015590B1 (pt) Implantes intravitreos de ácido polilático-co-glicólico (alga) contendo lupeol ou derivados aplicados ao tratamento de doenças oculares com base angiogênica como a retinopa tia diabética
HK1217452A1 (zh) 含有前列腺胺的眼内植入物